Amelogenesis imperfecta (AI) represents hereditary conditions affecting the quality and quantity of enamel. Six genes are known to cause AI (AMELX, ENAM, MMP20, KLK4, FAM83H, and WDR72). Our aim was to determine the distribution of different gene mutations in a large AI population and evaluate phenotype-genotype relationships. Affected and unaffected family members were evaluated clinically and radiographically by one examiner. Genotyping was completed using genomic DNA obtained from blood or saliva. A total of 494 individuals were enrolled, with 430 (224 affected, 202 unaffected, and 4 not definitive) belonging to 71 families with conditions consistent with the diagnosis of AI. Diverse clinical phenotypes were observed (i.e. hypoplastic, hypocalcified, and hypomaturation). Genotyping revealed mutations in all 6 candidate genes. A molecular diagnosis was made in 132 affected individuals (59%) and in 26 of the families (37%). Mutations involved 12 families with FAM83H (46%), 6 families with AMELX (23%), 3 families with ENAM (11%), 2 families with KLK4 and MMP20 (8% for each gene), and 1 family with a WDR72 mutation (4%). Phenotypic variants were associated with allelic FAM83H and AMELX mutations. Two seemingly unrelated families had the same KLK4 mutation. Families affected with AI where candidate gene mutations were not identified could have mutations not identifiable by traditional gene sequencing (e.g. exon deletion) or they could have promoter sequence mutations not evaluated in this study. However, the results suggest that there remain new AI causative genes to be identified.

Keywords:
Enamel, Amelogenesis imperfecta, Gene, Mutation, Phenotype, Genotype
1.
Aldred, M.J., P.J.M. Crawford (1995) Amelogenesis imperfecta – towards a new classification. Oral Dis 1: 2–5.
2.
Backman, B. (1988) Amelogenesis imperfecta – clinical manifestations in 51 families in a northern Swedish country. Scand J Dent Res 96: 505–516.
3.
Backman, B., A.K. Holm (1986) Amelogenesis imperfecta: prevalence and incidence in a northern Swedish county. Community Dent Oral Epidemiol 14: 43–47.
4.
Chosack, A., E. Eidelman, I. Wisotski, T. Cohen (1979) Amelogenesis imperfecta among Israeli Jews and the description of a new type of local hypoplastic autosomal recessive amelogenesis imperfecta. Oral Surg Oral Med Oral Pathol 47: 148–156.
5.
Crawford, P., M. Aldred (1988) Amelogenesis imperfecta: autosomal dominant hypomaturation-hypoplasia type with taurodontism. Br Dent J 164: 71–73.
6.
El-Sayed, W., D.A. Parry, R.C. Shore, M. Ahmed, H. Jafri, Y. Rashid, S. Al-Bahlani, S. Al Harasi, J. Kirkham, C.F. Inglehearn, A.J. Mighell (2009) Mutations in the beta propeller WDR72 cause autosomal-recessive hypomaturation amelogenesis imperfecta. Am J Hum Genet 85: 699–705.
7.
Fukumoto, S., T. Kiba, B. Hall, N. Iehara, T. Nakamura, G. Longenecker, P.H. Krebsbach, A. Nanci, A.B. Kulkarni, Y. Yamada (2004) Ameloblastin is a cell adhesion molecule required for maintaining the differentiation state of ameloblasts. J Cell Biol 167: 973–983.
8.
Hart, P.S., T.C. Hart, M.D. Michalec, O.H. Ryu, D.G. Simmons, S.P. Hong, J.T. Wright (2004) Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 41: 545–549.
9.
Igarashi, T., J. Inatomi, T. Sekine, S.H. Cha, Y. Kanai, M. Kunimi, K. Tsukamoto, H. Satoh, M. Shimadzu, F. Tozawa, T. Mori, M. Shiobara, G. Seki, H. Endou (1999) Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet 23: 264–266.
10.
Iwasaki, K., E. Bajenova, E. Somogyi-Ganss, M. Miller, V. Nguyen, H. Nourkeyhani, Y. Gao, M. Wendel, B. Ganss (2005) Amelotin – a novel secreted, ameloblast-specific protein. J Dent Res 84: 1127–1132.
11.
Kestler, D.P., J.S. Foster, S.D. Macy, C.L. Murphy, D.T. Weiss, A. Solomon (2008) Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms. Mol Med 14: 318–326.
12.
Kim, J.W., S.K. Lee, Z.H. Lee, J.C. Park, K.E. Lee, M.H. Lee, J.T. Park, B.M. Seo, J.C. Hu, J.P. Simmer (2008) FAM83H mutations in families with autosomal-dominant hypocalcified amelogenesis imperfecta. Am J Hum Genet 82: 489–494.
13.
Kim, J.W., F. Seymen, B.P. Lin, B. Kiziltan, K. Gencay, J.P. Simmer, J.C. Hu (2005a) ENAM Mutations in autosomal-dominant amelogenesis imperfecta. J Dent Res 84: 278–282.
14.
Kim, J.W., J.P. Simmer, T.C. Hart, P.S. Hart, M.D. Ramaswami, J.D. Bartlett, J.C. Hu (2005b) MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet 42: 271–275.
15.
Kim, J.W., J.P. Simmer, B.P. Lin, F. Seymen, J.D. Bartlett, J.C. Hu (2006) Mutational analysis of candidate genes in 24 amelogenesis imperfecta families. Eur J Oral Sci 114(suppl 1): 3–12, discussion 39–41, 379.
16.
Krebsbach, P.H., S.K. Lee, Y. Matsuki, C.A. Kozak, K.M. Yamada, Y. Yamada (1996) Full-length sequence, localization, and chromosomal mapping of ameloblastin. J Biol Chem 271: 4431–4435.
17.
Lagerstrom, M., N. Dahl, Y. Nakahori, Y. Nakagome, B. Backman, U. Landegren, U. Pettersson (1991) A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). Genomics 10: 971–975.
18.
Nussier, M., O. Yassin, T.C. Hart, A. Samimi, J.T. Wright (2004) Phenotypic diversity and revision of the nomenclature for autosomal recessive amelogenesis imperfecta. Oral Surg Oral Med Oral Pathol 97: 220–230.
19.
OMIM (2010) Online Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/omim.
20.
Parry, D.A., A.J. Mighell, W. El-Sayed, R.C. Shore, I.K. Jalili, H. Dollfus, A. Bloch-Zupan, R. Carlos, I.M. Carr, L.M. Downey, K.M. Blain, D.C. Mansfield, M. Shahrabi, M. Heidari, P. Aref, M. Abbasi, M. Michaelides, A.T. Moore, J. Kirkham, C.F. Inglehearn (2009) Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis imperfecta. Am J Hum Genet 84: 266–273.
21.
Rowley, R., F.J. Hill, G.B. Winter (1982) An investigation of the association between anterior open-bite and amelogenesis imperfecta. Am J Orthod 81: 229–235.
22.
Sundell, S. (1986) Hereditary amelogenesis impertecta: an epidemiological, genetic and clinical study in a Swedish child population. Swed Dent J 31(suppl): 1–38.
23.
Vitiello, C., P. D’Adamo, F. Gentile, E.M. Vingolo, P. Gasparini, S. Banfi (2005) A novel GJA1 mutation causes oculodentodigital dysplasia without syndactyly. Am J Med Genet A 133A: 58–60.
24.
Witkop, C.J. (1957) Hereditary defects in enamel and dentin. Acta Genet Stat Med 7: 236–239.
25.
Witkop, C.J., Jr. (1989) Amelogenesis imperfecta, dentinogenesis imperfecta and dentin dysplasia revisited, problems in classification. J Oral Pathol 17: 547–553.
26.
Witkop, C.J., Jr., W. Kuhlmann, J. Sauk (1973) Autosomal recessive pigmented hypomaturation amelogenesis imperfecta: report of a kindred. Oral Surg Oral Med Oral Pathol 36: 367–382.
27.
Witkop, C.J., J.J. Sauk (1976) Heritable defects of enamel; in Stewart, R., G. Prescott (eds): Oral Facial Genetics. St. Louis, C.V. Mosby, pp 151–226.
28.
Wright, J.T., S. Frazier-Bowers, D. Simmons, K. Alexander, P. Crawford, S.T. Han, P.S. Hart, T.C. Hart (2009) Phenotypic variation in FAM83H-associated amelogenesis imperfecta. J Dent Res 88: 356–360.
29.
Wright, J.T., P.S. Hart, M.J. Aldred, W.K. Seow, P.J.M. Crawford, S.P. Hong, C. Gibson, T.C. Hart (2003) Relationship of phenotype and genotype in X-linked amelogenesis imperfecta. Connect Tissue Res 44(suppl): 72–78.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.